Tempus AI News - August 19, 2026
Tempus AI Rockets 22% on a Cancer Vaccine Breakthrough — But Can a Single Trial Justify a $1.5 Billion Bet?
Shares of Tempus AI surged 22% to $60.23 Wednesday after a landmark clinical trial handed the company an unexpected windfall of validation. A personalized...
Tempus AI Surges, as Cancer Vaccine Success Validates $1.5B Personalis Deal
Tempus AI shares surged more than 20% on Wednesday. The rally followed news that a personalized mRNA cancer vaccine from Merck and Moderna succeeded in a...
🟢 Tempus AI is trading 12.64% up today; no clear catalyst identified
Tempus AI is trading 12.64% up at $55.40, with no clear company-specific catalyst identified for August 19, 2026. - Latest listed releases were the August 4...
🟢 Tempus AI is trading 13.19% up in pre-market despite no identified catalyst
Tempus AI is trading 13.19% up at $55.87 after no clear company-specific announcement was identified for August 19, 2026. - The latest listed company releases...
🟢 Tempus AI is trading 5% up in pre-market; catalyst unclear
Tempus AI is trading at $52.03 (+5.41%) with no clear fresh catalyst identified. - No fresh August 19, 2026 company-specific announcement or earnings release...